Completed Studies

Archives

  • The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection (T-cell Study; SLVP030)
  • Innate and Acquired Immunity to Influenza Infection and Immunization (B-cell Study; SLVP029)
  • Genetic and Environmental Factors in the Response to Influenza Vaccination; SLVP028 (Twin Study)
  • Human Cytomegalovirus Infection and Immunity in Healthy Adults (SLVP001) (Sponsor: NIH-Aviron)
  • Core B: Clinical Research Support. (Under PPG: Antiviral Immune Mechanisms in Early Childhood, SLVP004). (Sponsor: NIH, Dean’s Postdoctoral Fellowship)
  • Phase III, Safety and Immunogenicity of Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis (TdcP) Vaccine Compared to Tetanus and Diphtheria Toxoids Adsorbed (Td) in Adolescents and Adults 11-64 Years of Age. (SLVP005) (Sponsor: Aventis Pasteur)
  • Phase IV, Comparison of the Initial Immune Response, Antibody Persistence, and Clinical Course Post Vaccination in Siblings Receiving the Oka/Merck Varicella Vaccine (VARIVAX) at Kaiser Permanente Medical Group of Northern California. (Sponsor: AAHP, CDC Prime, CISA)
  • Phase I/II, A Multi-Center, Double Blind, Randomized Dose-Response Study of Dryvax Vaccine against Smallpox in Previously Vaccinated Adults. (DMID 02-007) (Sponsor: NIH-DMID, VTEU)
  • Cellular Immune Response in Children with Confirmed Influenza A Infection. (Sponsor: NIH, Vanderbilt)
  • Phase IV, Studies of Extensive Swelling Reactions after Booster Doses of Acellular Pertussis Combined with Diphtheria and Tetanus Vaccines: 5th Dose Vaccination Study. (Sponsor: AAHP, CDC Prime, CISA)
  • Health Impact of Congenital Cytomegalovirus Infection. (SLVP008) (Sponsor: NIH, Dekker R01)
  • Phase IV, Immune Response to Influenza in Young Children Immunized with Trivalent Inactivated Influenza Vaccine (TIV). (Sponsor: NIH-CCHI U19)
  • Influenza-Specific CTL Responses in Adenoids and Tonsils (samples from Vanderbilt). (Sponsor: NIH-CCHI U19)
  • U19 Year 1, 2+3: Phase IV, Influenza Immunity: Mechanisms Against a Pandemic Respiratory Virus (Clinical Core). (Sponsor: NIH-CCHI U19)
  • Clinical Consultation of Adverse Events Following Immunizations: A Registry of Patient Outcomes and Provider Care; A Repository of Selected Patient Specimens. ((Sponsor: CDC/AHIP, CISA)
  • U19 Year 2 – Phase IV, Influenza Immunity: Protective Mechanisms Against a Pandemic Respiratory Virus: Open-label Study of the Immunogenicity of an Inactivated Influenza Vaccine Given to Previously Unimmunized Children Between 6 Months and 5 Years of Age. Subset Follow-up for Nasal Samples for Influenza PCR Subset Follow-up for Nasal Swab Samples for Influenza PCR (SLVP010). (Sponsor: NIH-CCHI U19)
  • U19 Years 2+3 – Phase IV, Influenza Immunity: Protective Mechanisms against a Pandemic Respiratory Virus: A Randomized Comparison of the Immune Response to Either Inactivated or Live, Attenuated Influenza Vaccine in Children 5-9 Years of Age. Subset Follow-up for Nasal Swab Samples for Influenza PCR. A Randomized Comparison of the Immune Response to Either Inactivated or Live, Attenuated Influenza Vaccine in Children 5-9 Years of Age. Subset Follow-up for NP Samples for Influenza PCR (SLVP011). (Sponsor: NIH-CCHI U19)
  • A Phase I/II Clinical Trial Evaluating the Safety and Immunogenicity OF LC16m8, A Modified Vaccinia Vaccine, in Healthy Volunteers (SLVP012). (Sponsor: Vaxgen, Inc.)
  • Phase IV, Immunogenicity and Safety of Vaccines Administered to Preterm Infants. Sponsor: CDC/AHIP, CISA)
  • Testing the Optimum Time to Distribute Parental Immunization Materials. (Sponsor: CDC/AHIP, CISA)
  • Phase II, Immunogenicity and Safety of a Split, Inactivated, Trivalent Influenza Vaccine Administered by Intradermal Route Compared to an Intramuscular Vaccination with Fluzone® in Healthy Adults (e-protocol #3233, DMID 05-0075). (Sponsor: NIH-DMID (VTEU)
  • A Randomized, Placebo-controlled, Phase I/II, Dose-ranging Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza A/H5N1 Vaccine Given Alone or Combined with Adjuvants in Healthy Adults (DMID 04-062). (Sponsor: NIH-DMID (VTEU)
  • A Phase III, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study To Evaluate The Immunogenicity, Safety, and Tolerability of CSL Limited Inactivated Influenza Vaccine in Adults > 18 to < 65 Years of Age (DMID 06-0016). (Sponsor: NIH-DMID (VTEU)
  • Effectiveness of the Influenza Vaccine in Preventing Laboratory-Confirmed Flu in Infants and in Unvaccinated Household Contacts.
  • A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Clinical Trial of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Immunization With Inactivated, Vero Cell-Culture Derived Influenza A/H5N1 Vaccine Given Alone or With Aluminum Hydroxide to Healthy Young Adults (DMID 06-0052). (Sponsor: NIH-DMID, VTEU)